Sort
130,381 grants matching “hiv”
Pathogenic determinants of the SIV envelope transmembrane cytoplasmic domain
$830,518James A Hoxie · University Of Pennsylvania · R01 · FY2011 · AI
Developing small molecule therapeutics for Ebola hemorrhagic fever virus
$830,518Arnab Basu · Microbiotix, Inc · R01 · FY2012 · AI
Human Monoclonal Antibodies Against Cancer
$830,477Dimiter S Dimitrov · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Drug Use, Social Context, and HIV Risk in Homeless Youth
$830,457Joan S Tucker · Rand Corporation · R01 · FY2009 · DA
In vivo CRISPR engineering of B cells to produce anti-HIV broadly neutralizing antibodies using novel nanoparticles
$830,363Jennifer Eileen Adair · Univ Of Massachusetts Med Sch Worcester · R01 · FY2025 · AI
Structure-function studies of the membrane-interacting domains of HIV-1 Env spike
$830,356Bing Chen · Boston Children'S Hospital · R01 · FY2018 · AI
Gene Therapy Basic Research to Treat Inherited Primary Immune Deficiencies
$830,307Harry L Malech · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
Identification and eradication of HIV tissue reservoirs in a relevant animal mode
$830,244Binhua Ling · Tulane University Of Louisiana · R01 · FY2011 · AI
Human Genes that Influence HIV-1 Replication, Pathogenesis, and Immunity in IVDUs
$830,209Jeremy Luban · Univ Of Massachusetts Med Sch Worcester · DP1 · FY2012 · DA
Optimizing HIV counseling testing and referral through an adaptive drug use intervention
$830,138Rob B Stephenson · University Of Michigan At Ann Arbor · R01 · FY2017 · DA
Multitargeted Microbicide Combinations to Block HIV
$830,132Betsy C. Herold · Icahn School Of Medicine At Mount Sinai · U19 · FY2006 · HD
The combinatorial effects of Opiates and the emerging promoter-variant strains of HIV-1 subtype C on HIV neuropathogensis and latency
$830,071Shilpa J Buch · University Of Nebraska Medical Center · R01 · FY2018 · DA
Self-Powered Sample Concentrating and CRISPR-based Biosensing for Moile HIV-1 RNA Detection
$830,055Changchun Liu · University Of Connecticut Sch Of Med/Dnt · R33 · FY2023 · AI
Project 3: PREVENT: A first-in-human clinical trial of Griffithsin, an HIV entry
$830,038Rhonda Metter Brand · University Of Louisville · U19 · FY2018 · AI
Biodiversity of Vietnam and Laos
$830,025Djaja D Soejarto · University Of Illinois At Chicago · U01 · FY2006 · TW
Institutional Collaboration between LSTM and CDC and Prevention on Malaria(U01)
$830,000Feiko Olaf Ter Kuile · Tmliverpool School Of Tropical Medicine · U01 · FY2012 · CK
HEALTH PROMOTION & DISEASE PREVENTION RESEARCH CENTER
$830,000Daniel S Blumenthal · Morehouse School Of Medicine · U48 · FY2009 · DP
MALAWI HIV COUNSELING AND TESTING, TRAINING AND MENTORING PROGRAMME
$830,000Wellington Enock Limbe · Malawi Aids Counseling & Resource Org · U2G · FY2011 · PS
New Drosophila, mouse, and human podocyte models to study HIV-APOL1-G1 associated chronic kidney diseases
$829,985Patricio Ernesto Ray · University Of Virginia · R01 · FY2025 · DK
Global Analysis of Cellular Networks Involved In Restriction of HIV Replication
$829,875Sumit K Chanda · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2014 · AI
Still Climbin': A Randomized Controlled Trial of an Intervention to Improve Coping with Discrimination, Address Medical Mistrust, and Reduce Health Disparities among Black Sexual Minority Men
$829,836Laura M Bogart · Rand Corporation · R01 · FY2025 · MD
TRIAD-2 Center for Health Disparities Research
$829,781Debra C Wallace · University Of North Carolina Greensboro · P20 · FY2014 · MD
Limiting HIV establishment and maintenace by preserving intestinal immunity
$829,776Siddappa N Byrareddy · University Of Nebraska Medical Center · R01 · FY2019 · AI
Early Innate/IgA Anti-HIV/SIV Response in Exposed Uninfected
$829,776Luis J. Montaner · Wistar Institute · R01 · FY2011 · AI
Small molecule-induced degradation of dengue proteins as an antiviral strategy
$829,756Priscilla Li-Ning Yang · Harvard Medical School · R01 · FY2020 · AI